Context Therapeutics Inc., a clinical-stage biopharmaceutical company, has announced the presentation of a Trial in Progress poster for its Phase 1 clinical trial of CTIM-76 at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The trial focuses on CTIM-76, a Claudin 6 x CD3 T cell engager, and is being evaluated for its safety and efficacy in treating CLDN6-positive advanced or metastatic ovarian, endometrial, and testicular cancers. The study, which began dosing its first patient in January 2025, is currently in the dosing cohort 3 phase. It is an open-label, dose escalation and expansion study expected to enroll up to 70 patients. The company plans to share initial data in the first half of 2026. Presentation materials will be available on Context Therapeutics' website.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。